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Abstract 
Objective: Dendritic cell-specific intercellular adhesion molecule (ICAM)-3 grabbing 
nonintegrin (DC-SIGN) participates in the initial stages of sexually transmitted HIV-1 infection 
by recognizing highly mannosylated structures presented in multiple copies on HIV-1 gp120 
and promoting virus dissemination. Inhibition of HIV interaction with DC-SIGN thus represents 
a potential therapeutic approach for viral entry inhibition at the mucosal level. 
Design: Herein we evaluate the efficacy in inhibiting HIV-1 infection and the potential toxicity 
of a multimeric glycomimetic DC-SIGN ligand (Dendron 12). 
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Methods: The ability of Dendron 12 to block HIV-1 infection was assessed in cellular and 
human cervical explant models. Selectivity of Dendron 12 towards DC-SIGN and langerin was 
evaluated by surface plasmon resonance studies. β chemokine production following 
stimulation with Dendron 12 was also analyzed. Toxicity of the compound was evaluated in 
cellular and tissue models. 
Results: Dendron 12 averted HIV-1 trans infection of CD4+ T lymphocytes in presence of 
elevated viral loads and prevented HIV-1 infection of human cervical tissues, under conditions 
mimicking compromised epithelial integrity, by multiple clades of R5 and X4 tropic viruses. 
Treatment with Dendron 12 did not interfere with the activity of langerin and also significantly 
elicited the production of the β chemokines MIP-1α, MIP-1β and RANTES. 
Conclusion: Dendron 12 thus inhibits HIV-1 infection by competition with binding of HIV to DC-
SIGN and stimulation of β-chemokine production. Dendron 12 represents a promising lead 
compound for the development of anti-HIV topical microbicides. 
 
Introduction 
HIV remains one of the leading causes of mortality and morbidity [1]. As the vast majority of 
HIV-1 infections occur via sexual transmission through mucosal surfaces, the development of 
vaginal and rectal topical microbicides represents a promising approach to prevent sexually 
transmitted HIV-1 infection. 
Dendritic cell-specific intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN) is 
involved in the initial step of HIV-1 sexually transmitted infection and it may be considered a 
promising therapeutic target [2,3]. 
Myeloid immature dendritic cells located in mucosal tissue of vagina, cervix and rectum 
express DC-SIGN and are among the first cells to encounter sexually transmitted HIV [4–6]. 
Upon HIV-1 binding to DC-SIGN, the virus escapes (at least partially) degradation into 
lysosomes. Rather, it is internalized into endosomes and multivescicolar bodies, in which it is 
protected from degradation and retained in a high infective state [7–9]. Dendritic cells 
transmit the virus in trans to adjacent CD4+ T lymphocytes in genital mucosae or, after 
migration to lymphoid tissue, to CD4+ T lymphocytes resident in lymphoid tissue, promoting 
HIV-1 dissemination [10,11]. DC-SIGN, facilitating HIV-1 interaction with CD4 and co-receptors, 
also enhances dendritic cell infection in cis, that results in long-term transmission of HIV 
[12,13]. 
In addition, binding of HIV-1 to DC-SIGN activates signaling pathways that modulate Toll-like 
receptor signaling, inducing immunosuppressive responses and triggering HIV replication and 
transmission [14–17]. 
DC-SIGN specifically recognizes the high mannose glycan (Man9), presented in multiple copies 
on HIV-1 gp120 [8,18]. Fragments of Man9 terminated by a di-mannoside or a tri-mannoside 
bind to DC-SIGN almost as efficiently as the entire Man9[19]. Chemically synthesized analogs 
of (Man)9 terminal di-saccharides and tri-saccharides are more resistant to hydrolysis by 
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glycosydases than the corresponding natural oligosaccharides and interact efficiently with DC-
SIGN [20]. These analogs can be linked to tetravalent (dendrons) scaffolds to obtain 
compounds endowed with stronger binding affinities to DC-SIGN [21,22]. Such compounds can 
compete with binding of HIV gp120 to DC-SIGN and are suitable for the development of new 
anti-HIV microbicides. 
We recently demonstrated that a tetravalent dendron containing four copies of a linear 
pseudo-mannotrioside (Dendron 12) was able to inhibit HIV-1 trans infection of CD4+ T 
lymphocytes [23]. 
Experimental models based on infection with HIV of explants taken from human uterine cervix, 
albeit with some limitations, allow a better approximation of the conditions in vivo compared 
to cellular models [24–27]. Thus, in this study a cervical explant model was exploited to assess 
the efficacy in inhibiting HIV-1 infection and the toxicity of Dendron 12, with the purpose of 
evaluating if the compound is a suitable candidate for the development as topical microbicide. 
 
Material and methods 
Cell culture 
B-THP1 and B-THP1/DC-SIGN cells (contributed by Drs Li Wu and Vinet N. KevalRamani) were 
cultured as described [23]. 
Virus 
The following HIV-1 strains were used: BaL (contributed by Drs. S. Gartner, M. Popovic and R. 
Gallo; DU174 (Source: Dr L Morris); the R5 and X4 tropic primary isolates 8 g and DPMVF 
(provided by Professor Stefano Aquaro). 
Inhibition of HIV infection in trans 
Human CD4+ T lymphocytes were purified from peripheral blood of volunteer healthy donors 
following written consent, and activated as described [23]. Dendron 12, synthesized as 
described [23], was diluted to desired concentration into culture medium [Roswell Park 
Memorial Institute (RPMI) 160 with 20% fetal bovine serum (FBS), penicillin and streptomycin 
and L-glutamine, all from Euroclone, Siziano, Italy]. B-THP1/DC-SIGN or B-THP1 cells 
(106 cells/ml) were preincubated with Dendron 12 (250 μmol/l), or culture medium alone for 
30 min prior to exposure to BaL (virus titer ranging from 5 TCID50 to 80 TCID50), in the 
continued presence of the inhibitor 3 h at 37°C. After extensive washing, B-THP1/DC-SIGN cells 
were co-cultured with activated human CD4+ T cells as previously described [23]. 
Human cervical explants infection 
Cervical tissue was obtained, following written informed consent, from premenopausal 
women, HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) seronegative and without 
current genital infection, undergoing therapeutic hysterectomy at Unit of Obstetrics and 
Gynaecology of Sacco Hospital (Milan, Italy). The study was approved by the local ethic 
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committee and conducted in compliance with international guidelines and local laws. 
Endocervical 3 mm × 3 mm explant biopsies comprised both epithelium and stromal tissue. 
Within 1 h after obtaining tissues the explants were extensively washed. Then explants were 
either immediately treated with the Dendron 12 and infected with R5 tropic strains or were 
prestimulated for 2 days in presence of IL-2 (R&D systems, Minneapolis, Minnesota, USA) and 
phytohaemagglutinin (PHA) (Sigma–Aldrich, Saint Louis, Missouri, USA) prior to X4 tropic 
DPMVF exposure. 
Explants were pretreated 30 min at 37°C with different concentrations of Dendron 12. 
Afterwards explants were exposed to HIV-1 BaL, DU174 (both 2.6 × 104 TCID50), 8 g or DPMVF 
(both 104 TCID50) in the continued presence of the compound 3 h at 37°C. Subsequently 
explants were washed with RPMI. Unstimulated explants were cultured in RPMI medium 
supplemented with 20% FBS, penicillin and streptomycin, L-glutamine (Euroclone) and 
gentamycin (Sigma–Aldrich) at 37°C and 5% CO2. Stimulated explants were cultured under the 
same conditions in presence of IL-2. Supernatants were collected 3 and 7 days post infection. 
p24 ELISA 
p24 concentration in the supernatants was assayed by Alliance HIV-1 p24 Antigen kit (Perkin 
Elmer, Waltham, Massachusetts, USA). Plates were read using the IMark microplate reader 
equipped with Microplate Manager 6 software (Biorad, Segrate, Italy). 
Toxicity on peripheral blood mononuclear cells 
Peripheral blood mononuclear cells (PBMC), purified from peripheral blood of healthy donors 
as described [23], were incubated with different concentrations of Dendron 12 for 3 or 7 days. 
The apoptosis was monitored evaluating the percentage of dead cells by staining with 7-AAD 
(Beckman Coulter, Fullerton, California, USA). Flow cytometric analyses were performed using 
a CYTOMICS FC-500 flow cytometer interfaced with CXP21 software (Beckman Coulter). 
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay 
Toxicity of Dendron 12 was determined by a 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide-based assay (Sigma–Aldrich). Viable explants reduce MTT to 
formazan crystals. Explants were cultured with increasing concentration of Dendron 12 diluted 
in medium culture for 3 and 7 days. The 50% of medium culture (containing the different 
concentration of Dendron 12) was changed at day 3. After culturing, explants were washed 
and incubated in medium RPMI without phenol red and 10% FBS and MTT. Formazan was 
dissolved by MTT solubilization solution and formazan absorbance was measured at 595 nm. 
Differentiation and treatment of monocyte-derived dendritic cells 
CD14+ monocytes were separated from PBMCs using the CD14+ microbeads (Miltenyi Biotech, 
Bergisch Gladbach, Germany) following manufacturer's instruction. Monocytes were 
differentiated into iDCs by culturing them in presence of IL-4 (20 ng/ml) and granulocyte-
macrophage colony-stimulating factor (20 ng/ml) (R&D Systems) for 6 days. DC-SIGN 
expression was checked by staining with anti human DC-SIGN-PE monoclonal antibody (clone 
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AZND1, Beckman Coulter) and flow cytometric analysis. Monocyte-derived dendritic cells 
(MDDCs) were treated with Dendron 12. Supernatants were harvested and RNA extracted 
from cells after 3, 24 and 72 h. β chemokine concentration in culture supernatants was 
evaluated using DuoSet kits (R&D Systems). 
RNA extraction and real-time PCR 
RNA was extracted using the acid guanidium thiocyanate–phenol–chloroform method and 
purified from genomic DNA with RNase-free DNase (RQ1 DNase, Promega, Madison, 
Wisconsin, USA). RNA was reverse-transcribed using random examer primers and M-MLV 
reverse transcriptase (Clontech, Palo Alto, California, USA). cDNA quantification for 
macrophage inflammatory protein (MIP)-1α, MIP-1β, RANTES (regulated upon activation, 
normal T-cell expressed, and secreted) and glycerAldehyde 3-phosphate dehydrogenase 
(GAPDH) was performed by real-time PCR (DNA Engine Opticon 2; MJ Research, Ramsey, 
Minnesota, USA). Reactions were performed using a SYBR Green PCR mix (Finnzymes, Espoo, 
Finland). Results were expressed as ΔΔCt and presented as ratios between the target gene and 
the GAPDH housekeeping mRNA. 
Surface plasmon resonance analysis 
Extracellular domain (ECD) of langerin (residue 68–328) and DC-SIGN (residue 66–404) was 
overexpressed and purified as described [28,29]. Surface plasmon resonance (SPR) 
experiments were performed on a Biacore 3000 using functionalized CM4 sensor chips and the 
corresponding reagents from Biacore. Two flow cells were activated as described [30]. Flow 
cell one was blocked with ethanolamine and used as a control surface. The second one was 
treated with BSA-Manα1–3[Manα1–6]Man (Man-BSA, Dextra) (60 μg/ml) in 10 mmol/l acetate 
buffer, pH 4. Remaining activated groups were blocked with ethanolamine. The final density 
immobilized on the surface of the second flow cell was 5200 RU. The Man-BSA used to 
functionalize CM4 chip harbors 12 glycosylation sites. The affinities for DC-SIGN ECD and 
langerin ECD of pseudo-mannotrioside and D-mannose were estimated by an inhibition assay, 
as described [22,31]. Each lectin was injected onto the Man-BSA surface, at 20 μmol/l alone or 
in presence of an increasing concentration of compounds. Injections were performed at 5 
μl/min using 25 mM Tris-HCl, pH 8, 150 mM NaCl, 4 mmol/l CaCl2, and 0.005% of P20 
surfactant as running buffer. The surface was regenerated by 1’ injection of 50 mmol/l EDTA, 
pH 8. The IC50 values were determined as described [22,31]. 
 
Results 
Dendron 12 inhibits trans infection in presence of HIV-1 elevated viral load 
We firstly examined whether the Dendron 12 was able to inhibit the trans infection in the 
presence of elevated viral load. B-THP1/DC-SIGN cells were used as model to mimic HIV 
transmission to CD4+ T cells, as previously described [6,23,32]. B-THP1/DC-SIGN cells were 
preincubated 30 min in the presence or in absence of Dendron 12 and then exposed to 
different inoculums of HIV-1 Bal. Then, B-THP1/DC-SIGN cells were washed and co-cultured 
with activated CD4+ T cells. At lower viral concentration inhibition of BaL transmission to CD4+ 
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T cells was almost complete. Even at higher viral load (40 and 80 TCID50) the Dendron 12 was 
able to counteract the transmission of the virus to CD4+ T lymphocytes (more than 92% of 
inhibition) (Fig. 1a). 
Selectivity towards DC-SIGN 
Both langerin and DC-SIGN recognize Man9 on gp120, but have distinct specificities towards 
complex oligosaccharides [33–36]. Specificity of pseudo-mannotrioside ligand for langerin and 
DC-SIGN was tested by competition experiments using SPR, as previously described [37]. A 
CM4 sensor chip was functionalized with BSA-mannotriose and a fixed amount of the 
extracellular domain of DC-SIGN and langerin was injected over the surface in the presence or 
absence of pseudo-mannotrioside or mannose (control). From the inhibition curves (Fig. 1b), 
an IC50 of the two ligands towards each lectins was evaluated (Fig. 1c). A limited difference in 
favor of DC-SIGN was observed for mannose. On the contrary, pseudo-mannotrioside is 20 
times more potent toward DC-SIGN than against langerin. Moreover, pseudo-mannotrioside is 
14 times more potent than D-mannose towards DC-SIGN. Indeed, the use of pseudo-
mannotrioside allows real improvement in affinity and in selectivity. 
Inhibition of HIV-1 infection of human cervical tissue by Dendron 12 
Endocervical tissue was obtained from premenopausal women, HIV, HBV and HCV 
seronegative, undergoing planned therapeutic hysterectomy. Explants were exposed to HIV-1 
in a nonpolarized manner, analogous to condition of compromised epithelium in vivo. As the 
laboratory adapted R5 strain HIV-1 BaL is able to infect resting tissue [25], explants were not 
activated to mimic physiological conditions. 
Explants were pretreated 30 min in absence or in presence of increasing concentration of 
Dendron 12 and then were exposed to BaL in the continued presence of compound. After 
washing to remove unbound Dendron 12 and virus, explants were maintained in culture up to 
7 days. Data represent p24 levels and are presented as the mean of five independent 
experiments, using explants from separate donors. Dendron 12 inhibited cervical explants BaL 
infection in dose-dependent manner (Fig. 2). At the higher concentration tested, Dendron 12 
reduced the infection by about 80%, at 3 and 7 days post infection. 
The ability of Dendron 12 to avert explant infection mediated by primary HIV-1 isolates was 
also verified. R5 tropic isolate 8 g was able to infect unstimulated tissue, but X4 tropic isolate 
DPMVF needed preactivation to induce infection (not shown). Explants unstimulated or 
preactivated 2 days with IL-2 and PHA were pretreated with increasing concentration of 
Dendron 12 and infected, respectively, with 8 g or DPMVF, as described before. Infection 
inhibition was dose-dependent. At the concentration of 1 mmol/l, infection by both isolates 
was reduced by more than 85%. At 0.05 mmol/l Dendron 12 decreases by 56% (day 3) and by 
40% (day 7) the infection mediated by 8 g (Fig. 3a and b), but the inhibitory effect against 
DPMVF was largely lost (Fig. 3c and d). 
Furthermore we evaluated the capability of Dendron 12 to block explant infection by Clade C 
R5 tropic strain DU174. Unstimulated explants were pretreated with the compound, exposed 
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to DU174 and cultured as described. Dendron 12 reduced DU174 infection in dose-dependent 
manner and by about 90% at 1 mM (Fig. 3e and f). 
Induction of β1 chemokines production by Dendron 12 
We wondered if, in addition to competitive inhibition of DC-SIGN, other mechanisms account 
for the antiviral effect of the compound 12. So we investigated if Dendron 12 stimulates the 
production of factors interfering with HIV infection. Due to difficulty of isolating sufficient 
amounts of primary mucosal dendritic cells, immature monocyte-derived dendritic cells 
(iMDDCs) that share with mucosal dendritic cells similar features and DC-SIGN expression, 
were used as a model [38]. iMDDCs were treated with Dendron 12 for 3, 24 and 72 h. 
Expression and production of β chemokines MIP-1α, MIP-1β, and RANTES following 
stimulation were analyzed by quantitative real-time PCR and ELISA. The treatment increased 
expression level of mRNA specific for MIP-1α, MIP-1β and RANTES (Fig. 4a-c) after 3 h. Also 
MIP-1α, MIP-1β and RANTES production increased after 24 and 72 h of stimulation (Fig. 4d-f). 
Evaluation of Dendron 12 toxicity 
Cytotoxicity against PBMCs was evaluated by labeling with 7-amino-actinomycin D (7-AAD) 
that identifies nonviable cells after Dendron 12 treatment. Compound exposure for 3 and 7 
days did not alter significantly the viability of PBMCs (Fig. 5a and b). 
To assess toxicity of Dendron 12 towards cervical tissue, effect of nonpolarized exposure of the 
compound on explants viability was monitored (Fig. 5c). After 3 and 7 days treatment in 
absence or in presence of different concentration of Dendron 12, viability was evaluated by a 
MTT-based assay. Viability of the compound treated explants was compared to viability of 
untreated control. No significant difference between control and treated explants was 
observed up to a concentration of 1 mM (the higher concentration tested in assessment of 
compound efficacy against HIV-1 infection). 
 
Discussion 
Three decades after HIV discovery HIV-AIDS pandemic continues and millions of people are 
infected every year. Thus, the development of effective, nontoxic and low-cost topical 
microbicides represents a valid alternative approach to prevent the sexual transmission of HIV 
[3]. However, so far almost all compounds failed to prevent HIV transmission in efficacy trials. 
A recent exception was a vaginal gel formulation of tenofovir that reduced HIV infection by 
50% [39]. 
Tenofovir and other topical microbicides can prevent localized infection of target cells in 
genital mucosae. However, dendritic cells DC-SIGN+ internalize and transport HIV to secondary 
lymphoid organs, rendering the virus inaccessible to inhibitory effect of the microbicides. 
Therefore inhibition of DC-SIGN is essential to block HIV-1 uptake and dissemination from 
migratory dendritic cells. 
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We have previously reported that the tetravalent Dendron 12 was able to block almost 
completely the HIV-1 trans infection of CD4+ T cells at micromolar range [23]. This compound 
exerts its activity by competitive inhibition of HIV-1 gp120 binding to DC-SIGN. In our initial 
experiments we demonstrated that Dendron 12 (at the same concentration previously 
assayed) even in presence of higher viral loads retains its ability to inhibit HIV-1 trans infection. 
This potent inhibitory activity is due both to elevate affinity for DC-SIGN of Dendron 12 
pseudo-trisaccharide units and to high avidity of binding, guaranteed by the tetravalent 
presentation on the compound scaffold. 
Different DC-SIGN inhibitors have been described so far. Dendrons displaying complex 
oligomannoses in high density inhibited binding of gp120 to DC-SIGN with IC50 in nanomolar 
range [40]. Nevertheless the complexity of the oligosaccharides used limits the possibility of a 
therapeutic application. Gold nanoparticles displaying mannosyl oligosaccharides are potent 
inhibitors of DC-SIGN-mediated HIV-1 trans infection of human PBMCs [41], but may have toxic 
effects because of gold accumulation. 
Unlike DC-SIGN, the C-type lectin langerin, expressed on Langerhans cells, appears to play a 
protective role against HIV infection. Langerhans cells are located in the stratified mucosal 
epithelia of female and male genital tissue. Both DC-SIGN and langerin recognize high 
mannose glycans on gp120 through their carbohydrate recognition domain (CRD). Recent data 
demonstrate that langerin prevents HIV transmission by Langerhans cells, at least in the 
presence of low concentration of the virus, promoting rapid degradation and clearance of HIV-
1 [32,33]. Using a biosensor with a SPR detection method we showed that the Dendron 12 is 
much more selective for DC-SIGN than for langerin. Considering the similarity between the 
CRD of DC-SIGN and langerin, the fact that the Dendron 12 does not interfere with langerin 
function is a remarkable advantage in view of developing new microbicides. 
The efficacy and the safety of the Dendron 12 were evaluated in a human cervical explant 
model. Endocervix is more susceptible to HIV-1, being lined by a single layer of columnar 
epithelium, and contains dendritic cell DC-SIGN+ in the subepithelial region [4,5,24]. Explants 
were exposed to HIV-1 to mimic a condition of compromised epithelium in vivo; condition that 
highly increases the risk of HIV infection. 
R5-tropic virus strains predominate during HIV-1 transmission in vivo and cause the majority of 
new infections [42]. The results obtained showed that Dendron 12 strongly reduced the 
infection of cervical explants by different HIV-1 R5 tropic strains, such as BaL, the primary 
isolate 8 g and the Clade C DU174. This may have a great impact, considering that Clade C is 
the most abundant subtype in all countries of Southern Africa and in some countries of eastern 
Africa and Asia, areas where the majority of HIV-1-infected people resides [43,44]. 
Rare cases of HIV-1 infection by X4-tropic strains were observed in CCR5Δ32 homozygotes and 
X4-tropic strain can infect immune activate human cervical tissue [25,42]. Dendron 12 was 
able to inhibit DPMVF primary X4-tropic strain infection at higher concentration assayed, but 
this effect was in part lost at lower concentrations of the compound. 
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Data obtained suggest that Dendron 12 might have additional mechanisms of action apart 
from competitive inhibition of HIV-1 binding to DC-SIGN. Flow cytometric studies indicate that 
treatment with Dendron 12 reduces DC-SIGN expression on B-THP1/DC-SIGN+ cells [23]. This 
effect may be due to increased internalization of the receptor after binding of the compound 
to DC-SIGN. 
Furthermore, Dendron 12 induced an increase of the production of β chemokines, such as 
MIP-1α, MIP-1β and RANTES, by iMDDCs. These β chemokines, natural ligands of CCR5, 
suppress HIV-1 R5 tropic strain replication, competing with the binding of the virus to CCR5 or 
inducing receptor internalization [45–47]. The Dendron 12, enhancing β chemokines 
production, could interfere, at least partially, with the direct infection of CCR5+ CD4+ T 
lymphocytes and macrophages located in genital mucosae. 
The Dendron 12 does not reduce the vitality of PBMCs and of explants. However, additional 
experiments, such as rabbit vaginal irritation assay [48], would be needed for a more accurate 
evaluation of potential toxic effects. 
Vaginal epithelium has limited permeability to particles greater than 30 nm [2]. However, the 
diameter of Dendron 12 is certainly below that threshold, so the compound could enter and 
diffuse into intact mucosal tissue. Furthermore the Dendron 12 scaffold can be easily modified 
to improve absorption of the compound, without decreasing affinity to DC-SIGN. 
The tetravalent Dendron 12 prevents HIV trans infection of CD4+ T lymphocytes at micromolar 
range, even in presence of elevated viral load, and displays high solubility in physiological 
media, a neglectable toxicity and a long-lasting effect. Moreover it inhibits in dose-dependent 
manner HIV-1 infection of human cervical explants. These features make the Dendron 12 a 
good candidate as a lead compound to develop new microbicide drugs. 
However, the Dendron 12 inhibits 80–90% of cervical explants HIV-1 infection, but cannot 
block it completely. To overcome these limitations, the structure of this compound can be 
improved in both the scaffold and the active pseudo-saccharide ligand to develop new ligands 
of DC-SIGN more effective and easier to synthesize. Furthermore, Dendron 12 (or its 
derivatives) can be used in combination with other molecules directed against different HIV 
targets. In particular multivalent structures, presenting on the same scaffold multiple copies of 
DC-SIGN and HIV co-receptor inhibitors, simultaneously blocking different HIV targets, could 
protect against different routes of HIV transmission. 
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Figure captions 
Figure 1. Evaluation of Dendron 12 ability to inhibit HIV-1 Bal trans infection in presence of 
increasing amounts of the virus (a) and selectivity to DC-SIGN (b,c).(a) After pretreatment with 
Dendron 12 (250 μm) or medium culture, B-THP-1/DC-SIGN cells were pulsed with BaL for 3 h. 
After washing cells were co-cultured 3 days with CD4+ T lymphocytes from healthy donors. 
Levels of infection were quantified by measuring p24 in the supernatants of co-cultures by 
ELISA. Data were obtained from three different healthy donors. Each donor was tested in 
duplicate. Values are mean ± SD. (b, c) SPR experiment results of DC-SIGN ECD and langerin 
ECD binding to Man-BSA/dextran surface inhibition by pseudo-mannotrioside (psTri) and D-
mannose. (b) Inhibition curves, and (c) lectin selectivity histograms. 
Figure 2. Inhibition of endocervical tissue infection mediated by HIV-1 Bal.After a 30 min 
pretreatment with the Dendron 12 or medium culture, endocervical explants were incubated 
3 h with BaL in the continued presence of indicated concentrations of Dendron 12. Then 
explants were washed and cultured for 7 days. Infection was monitored by ELISA 
measurement of p24 in explant culture supernatants at day 3 (a) and 7 (b) post infection. 
Values represent the mean ± SD of five independent experiments. *P < 0.05 (Student's t-test), 
**P < 0.01, ***P < 0.001. 
Figure 3. Inhibition of endocervical infection induced by HIV-1 primary isolates (8 g and 
DPMVF) and HIV-1clade C DU174.(a, b, e, f) Unstimulated explants were pretreated 30’ with 
Dendron 12 or medium culture and challenged with 8 g or DU174. (c, d) Explants immuno-
stimulated were pretreated 30’ with Dendron 12 or medium culture and infected with DPMVF. 
After washing explants were put in culture. Infection was monitored by ELISA measurement of 
p24 in explant culture supernatants at day 3 and 7 post infection. Values represent the 
mean ± SD of three independent experiments. *P < 0.05 (Student's t-test). 
Figure 4. β chemokines induction upon Dendron 12 (250 μmol/l) stimulation of human iMDDCs 
from healthy donors.(a–c) β chemokines expression following 3 h Dendron 12 (250 μmol/l) 
treatment. mRNA levels of MIP-1α (a), MIP-1β (b) and RANTES (c) were assessed by 
quantitative real-time PCR. Expression is normalized to GAPDH and shown as fold changes 
expression from the unstimulated sample, set as 1. (d–f) β chemokines protein production 
after stimulation with Dendron 12 (250 μmol/l). The concentration of MIP-1α (d), MIP-1β (e) 
and RANTES (f) in the culture supernatants was assayed by ELISA at 24 and 72 h. (a–f) Values 
represent the mean ± SD. 
Figure 5. Toxicity of compound 12.(a, b) Percentage of 7-AAD-positive (nonviable) PBMCs after 
3 or 7 days of incubation with different concentrations of Dendron 12 (0.25, 0.5 and 
0.1 mmol/l), or in the absence of the inhibitor (medium). Percentage of 7-AAD was determined 
by flow cytometry. Experiments were performed on PBMCs from three healthy donors. Values 
are mean ± SD. Effect of Dendron 12 on cervical explants viability (c). Endocervical explants, 
derived from the same donors, were exposed in nonpolarized manner to Dendron 12 or 
culture medium (control) for 3 and 7 days. Effect of Dendron 12 on tissue viability was 
determined by the MTT assay. Explants were weighted to normalize optical density of 
formazan yielded. Viability was expressed as percentage. Experiments were performed on 
explants from three donors. Data are reported as the average percentage viability (±SD).  
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